Advertisement

Adherence to antibiotic guidelines for erysipelas or cellulitis is associated with a favorable outcome

  • Camille KlotzEmail author
  • Johan Courjon
  • Céline Michelangeli
  • Elisa Demonchy
  • Raymond Ruimy
  • Pierre-Marie Roger
Original Article
  • 233 Downloads

Abstract

Outside areas of S. aureus strains resistant to methicillin (MRSA) in the community, no studies showed a relationship between the treatment for erysipelas or cellulitis and the outcome. We aimed to measure the impact of an internal therapeutic protocol, based on national guidelines on patients’ outcome. This study was based on the dashboard of the infectious diseases department, which prospectively includes 28 parameters for all admitted patients. We included community-acquired erysipelas and cellulitis; exclusion criteria were abscesses at admission; ear, nose, throat, or dental cellulitis; pyomyositis; and length of stay ≤ 2 days. Adherence to guidelines was defined by the use of amoxicillin, amoxicillin/clavulanic acid, clindamycin, or pristinamycin, alone or in combination or successively. A poor outcome was defined by surgical procedure or intensive care requirement or death occurring after 5 days or more of antibiotic therapy. From July 2005 to June 2017, 630 cases of erysipelas or cellulitis were included. Blood cultures performed in 567 patients (90%) were positive in 39 cases (6.9%). Adherence rate to guidelines was 65% (410 cases). A poor outcome was recorded in 54 (8.5%) patients, less frequently in case of adherence to guidelines: 26/410 (6.3%) vs 28/220 (12.7%), p = 0.007. In logistic regression analysis, two risk factors were associated with a poor outcome: peripheral arterial disease, AOR 4.80 (2.20–10.49); and bacteremia, AOR 5.21 (2.31–11.76), while guideline adherence was the only modifiable protective factor, OR 0.48 (0.26–0.89). In erysipelas and cellulitis, adherence to guidelines was associated with a favorable outcome.

Keywords

Erysipelas Cellulitis SSTI Antibiotic therapy Guidelines Outcome 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethics approval

Observational studies do not require ethical approval in France. Antimicrobial stewardship is promoted by the French National Health Agency. Internal dashboard is declared to French Data Protection Authority, number 1430722.

Informed consent

Patients or their relatives provided their written consent for digitization of their personal data for hospitalization purposes.

References

  1. 1.
    Erysipèle et fasciite nécrosante. Prise en charge. Conférence de consensus (2000) Med Mal Inf 30(Suppl 4):252–72Google Scholar
  2. 2.
    Bernard P, Christmann D, Morel M (2005) Management of erysipelas in French hospitals: a post-consensus conference study. Ann Dermatol Venereol 132:213–217CrossRefGoogle Scholar
  3. 3.
    Food and Drug Administration (2013) Guidance for industry: acute bacterial skin and skin structure infections developing drugs for treatment. www.fda.gov/downloads/Drugs/Guidances/ucm071185.pdf. Accessed 24 August 2016
  4. 4.
    Sartelli M, Malangoni MA, May AK, Viale P, Kao LS, Catena F et al (2014) WSES guidelines for management of SSTI. World J Emerg Surg 9:57CrossRefGoogle Scholar
  5. 5.
    Kamath RS, Sudhakar D, Gardner JG, Hemmige V, Safar H, Musher DM (2018) Guidelines vs actual management of skin and soft tissue infections in the emergency department. Open Forum Infect Dis 5(1):ofx188CrossRefGoogle Scholar
  6. 6.
    Jenkins TC, Knepper BC, Moore SJ, O’Leary ST, Caldwell B, Saveli CC et al (2014) Antibiotic prescribing practices in a multicenter cohort of patients hospitalized for acute bacterial skin and skin structure infection. Infect Control Hosp Epidemiol 35(10):1241–1250CrossRefGoogle Scholar
  7. 7.
    Lazzarini L, Conti E, Tositti G, Lalla F (2005) Erysipelas and cellulitis: clinical and microbiological spectrum in an Italian tertiary care hospital. J Inf Secur 51(5):383–389Google Scholar
  8. 8.
    Lipsky BB, Napolitano LM, Moran GJ, Vo L, Nicholson S, Kim M (2014) Inappropriate initial antibiotic treatment for complicated skin and soft tissue infections in hospitalized patients: incidence and associated factors. Diagn Microbiol Infect Dis 79(2):273–279CrossRefGoogle Scholar
  9. 9.
    Walsh TL, Chan L, Konopka CI, Burkitt MJ, Moffa MA, Bremmer DN et al (2016) Appropriateness of antibiotic management of uncomplicated SSTIs in hospitalized adult patients. BMC Infect Dis 16(1):721CrossRefGoogle Scholar
  10. 10.
    Roger PM, Demonchy E, Risso K, Courjon J, Leroux S, Leroux E et al (2017) Medical table: a major tool for antimicrobial stewardship policy. Med Mal Infect 47(5):311–318CrossRefGoogle Scholar
  11. 11.
    Smieja M (1998) MD FRCPC DTM&H, Current indications for the use of clindamycin: a critical review. Can J Infect Dis 9(1):22–28CrossRefGoogle Scholar
  12. 12.
    Gunderson CG, Martinello RA (2012) A systematic review of bacteraemia in cellulitis and erysipelas. J Inf Secur 64(2):148–155Google Scholar
  13. 13.
    Pulido-Cejudo A, Guzmán-Gutierrez M, Jalife-Montaño A, Ortiz-Covarrubias A, Martínez-Ordaz JL, Noyola-Villalobos HF et al (2017) Management of acute bacterial skin and skin structure infections with a focus on patients at high risk of treatment failure. Ther Adv Infect Dis 4(5):143–161PubMedPubMedCentralGoogle Scholar
  14. 14.
    Halilovic J, Heintz BH, Brown J (2012) Risk factors for clinical failure in patients hospitalized with cellulitis and cutaneous abscess. J Inf Secur 65(2):128–134Google Scholar
  15. 15.
    Figtree M, Konecny P, Jennings Z, Goh C, Krilis SA, Miyakis S (2010) Risk stratification and outcome of cellulitis admitted to hospital. J Inf Secur 60(6):431–439Google Scholar
  16. 16.
    Corey GR, Stryjewski ME (2011) New rules for clinical trials of patients with acute bacterial skin and skin-structure infections: do not let the perfect be the enemy of the good. Clin Infect Dis 52(Suppl. 7):S469–S476CrossRefGoogle Scholar
  17. 17.
    Joukhadar C, Klein N, Frossard M, Minar E, Stass H, Lackner E et al (2001) Angioplasty increases target site concentrations of ciprofloxacin in patients with peripheral arterial occlusive disease. Clin Pharmacol Ther 70(6):532–539CrossRefGoogle Scholar
  18. 18.
    Roger PM, Cua E, Courjon J, Landraud L, Carles M, Bernard E (2014) The impact of bacteraemia on the outcome of bone infections. Med Mal Infect 44(8):380–386CrossRefGoogle Scholar
  19. 19.
    Vazquez-Grande G, Kumar A (2015) Optimizing antimicrobial therapy of sepsis and septic shock: focus on antibiotic combination therapy. Semin Respir Crit Care Med 36(1):154–166CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Camille Klotz
    • 1
    Email author
  • Johan Courjon
    • 1
    • 2
  • Céline Michelangeli
    • 1
  • Elisa Demonchy
    • 1
  • Raymond Ruimy
    • 2
    • 3
  • Pierre-Marie Roger
    • 1
    • 2
    • 4
  1. 1.Infectiologie, Hôpital de l’ArchetCentre Hospitalier Universitaire de NiceNiceFrance
  2. 2.Faculté de MédecineUniversité de Nice Sophia-AntipolisNiceFrance
  3. 3.Bactériologie, Hôpital de l’ArchetCentre Hospitalier Universitaire de NiceNiceFrance
  4. 4.Groupe ElsanParisFrance

Personalised recommendations